Save up to $100 off Juvederm and Botox!

Save up to $100 off Juvederm and Botox!

Juvederm is a dermal filler that is excellent for smile lines and lip volumizing that can last anywhere from 6-9 months!

Botox is indicated for the treatment of moderate to severe wrinkles between the brows, upper forehead and crows feet!

Call us to make your appointment today! 949-499-1389

SCULPTRA SPECIAL

Coast Dermatology and Laser is currently offering $100 each Sculptra vial. Contact our office now to schedule your complimentary consultation with Dr. Glenn Goldberg and take advantage of this special offer.

To Find out more about Sculptra see below:

RESTYLANE SPECIAL. HURRY ENDS SOON!

Save $50 of each Restylane 1.0cc syringe. Hurry Offer ends 9/30/2011. Must print coupon and bring to appointment.

 For additional information on Restylane, see below and check out: http://www.restylaneusa.com/.

How does Restylane work?

Restylane adds volume and fullness to the skin to correct moderate to severe facial wrinkles and folds, such as the lines from your nose to the corners of your mouth (nasolabial folds).

Restylane works immediately by adding volume to smooth away wrinkles. A clear gel formulation of hyaluronic acid, Restylane is specifically formulated to act like your body’s own hyaluronic acid. So, you can use Restylane to visibly reduce moderate to severe facial wrinkles and folds for a younger-looking you.

Biocompatible with the human body, Restylane is eventually broken down naturally.

The Skin Cancer Foundation’s Response to the Release of the Final FDA Monograph

The Skin Cancer Foundation applauds the FDA for issuing its Final Sunscreen Monograph. According to the FDA, sunscreen ingredients are safe, and the benefit of regular sunscreen use far outweigh any potential risks.

Sun protection is an important public health issue, and sunscreen is an integral part of a comprehensive sun protection regimen that also includes seeking shade and wearing protective clothing, including sunglasses. Although science and technology have advanced over the past several years to dramatically improve the efficacy of sunscreens, there has long been a need to update the governmental regulations associated with them – particularly in the areas of UVA protection and product labeling.

This announcement is a significant advancement for the FDA, which brings awareness to and acknowledges the importance of UVA protection in the prevention of skin cancer. We hope that these new FDA rules, along with the recently updated standards set by The Skin Cancer Foundation’s Seal of Recommendation will enable consumers to choose sunscreens wisely.

- Steven Wang, MD, Committee Member, The Skin Cancer Foundation’s Photobiology Committee; Director of Dermatologic Surgery and Dermatology at Memorial Sloan-Kettering Cancer Center at Basking Ridge, NJ.


Here are the main points in the FDA’s new sunscreen rules:

•Sunscreens may be labeled “broad-spectrum” if they provide protection against ultraviolet A (UVA) and ultraviolet B (UVB) radiation.
•Only broad-spectrum sunscreens with a Sun Protection Factor (SPF) of 15 or higher can state that they protect again skin cancer if used as directed with other sun protection measures.


•Sunscreens with an SPF of 2-14 will be required to have a warning stating that the product has not been shown to help prevent skin cancer or early skin aging.


•The terms “sunblock”, “sweatproof” and “waterproof” are no longer allowed on sunscreen labels.


•A sunscreen may claim to be “water resistant”; however, the product must specify if it offers 40 minutes or 80 minutes of protection while swimming or sweating, based on standard testing. Sunscreens that are not water resistant must include a direction instructing consumers to use a water resistant sunscreen if swimming or sweating.


•Sunscreens cannot claim to provide sun protection for more than two hours without reapplication.


•Sunscreen manufacturers will have one year to comply with the FDA ruling; smaller companies will have two years.


•The ingredients in sunscreens marketed today have been used for many years and FDA does not have any reason to believe these products are not safe for consumer use.
•The FDA reiterated that sunscreen alone is not enough, and should be used in conjunction with a complete sun protection regimen, including seeking shade, wearing long pants, long-sleeved shirts, hats and sunglasses.

May - Skin Cancer Awareness Month

Since its inception in 1979, The Skin Cancer Foundation has always recommended using a sunscreen with an SPF 15 or higher as one important part of a complete sun protection regimen. Sunscreen alone is not enough, however. Read our full list of skin cancer prevention tips.

•Seek the shade, especially between 10 AM and 4 PM.

•Do not burn.

•Avoid tanning and UV tanning booths.

•Cover up with clothing, including a broad-brimmed hat and UV-blocking sunglasses.


•Use a broad spectrum (UVA/UVB) sunscreen with an SPF of 15 or higher every day.
For extended outdoor activity, use a water-resistant, broad spectrum (UVA/UVB)
sunscreen with an SPF of 30 or higher.


•Apply 1 ounce (2 tablespoons) of sunscreen to your entire body 30 minutes before going outside.
Reapply every two hours or immediately after swimming or excessive sweating.


•Keep newborns out of the sun. Sunscreens should be used on babies over the age of six months.


•Examine your skin head-to-toe every month.


•See your physician every year for a professional skin exam.

FDA Approves life-extending drug for metastatic melanoma

Melanoma is the deadliest form of skin cancer. When discovered early, it can usually be cured with surgery alone, but once it spreads (metastasizes) throughout the body, treatment options are limited. After decades of frustration for researchers, however, this promising new therapy is providing hope.

Yervoy (Ipilimumab) is a monoclonal antibody, an immune protein that binds to a molecule called CTLA-4 and inhibits it from functioning. CTLA-4 is a kind of brake on the immune system which keeps it from overfunctioning and thus attacking itself; by blocking it, ipilimumab kicks the immune system into higher gear so that it can identify, attack and eliminate melanoma cells.

In a large phase III trial of 676 advanced, inoperable melanoma patients published in 2010 in the New England Journal of Medicine, subjects previously treated unsuccessfully with other agents who received Yervoy or Yervoy plus a melanoma vaccine (gp100) lived on average 32 percent longer and had a 20 percent greater chance (45 percent vs. 25 percent) of surviving one year than those who received gp100 alone. And 24 percent were alive after two years, compared with just 14 percent of those treated with the other therapy. The impact of this trial cannot be overemphasized, as Yervoy was shown to be the first treatment ever to improve overall survival in advanced melanoma patients.

Now, in new study findings just announced, Yervoy was found to increase overall survival in inoperable stage III or stage IV metastatic melanoma patients who had not received prior therapy. The study specifically showed that ipilimumab combined with the chemotherapy dacarbazine increased overall survival, while dacarbazine alone did not. The findings will be submitted to the American Society of Clinical Oncology for potential presentation at its annual meeting in June.

Side effects of Yervoy are related primarily to the overactivation of the immune system, resulting in itching, skin rash and diarrhea. In fact, Yervoy may be more effective in patients who develop these side effects. However, in rare cases more dangerous side effects can occur, so patients are urged to enter studies with physicians well versed in managing its toxicities.

Another notable aspect of the treatment is that even in patients who ultimately see benefits, the disease may initially progress before it stabilizes or the tumor shrinks. For this reason, early clinical trials were at first deemed a failure before patients started to improve.

The medical community is enthusiastic about the approval of this new treatment. It represents a giant step towards the goal of curing this devastating disease.

http://myemail.constantcontact.com/Special-Deals-from-Coast-Dermatology---Laser-Surgery-Center.html?soid=1103564828058&aid=0rhYBwjPsiU

http://myemail.constantcontact.com/Special-Deals-from-Coast-Dermatology---Laser-Surgery-Center.html?soid=1103564828058&aid=0rhYBwjPsiU